ERBB2 and breast cancer: Quantitative changes in ER, PR and HER-2 immunoreactivity between primary breast cancer and BM were evaluated in 14 of 23 patients for ER and PR (no data were available for ten patients), and in 16 of 23 patients for HER-2 (no data for comparison in seven patients).